New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 10, 2014
10:01 EDTCNCE, HAR, LH, DGX, LINTA, HSNI, IBP, TLMR, EGRX, FLXNOn The Fly: Analyst Initiation Summary
Concert Pharmaceuticals (CNCE) initiated with a Buy at UBS and an Outperform at JMP Securities... Eagle Pharmaceuticals (EGRX) initiated with a Buy at Cantor and an Overweight at Piper Jaffray... Talmer Bancorp (TLMR) initiated with an Outperform at Keefe Bruyette, an Overweight at JPMorgan, a Strong Buy at Raymond James and an Outperform at RBC Capital... HSN, Inc. (HSNI) initiated with a Buy at UBS... Installed Building Products (IBP) initiated with a Buy at Deutsche Bank and a Neutral at SunTrust... Liberty Interactive (LINTA) initiated with a Buy at UBS and Craig-Hallum... Flexion (FLXN) initiated with a Buy at Needham... LabCorp (LH) assumed with a Neutral at Piper Jaffray... Quest Diagnostics (DGX) assumed with a Neutral at Piper Jaffray... Harman (HAR) initiated with an Outperform at Raymond James.
News For CNCE;EGRX;TLMR;IBP;HSNI;LINTA;DGX;LH;HAR;FLXN From The Last 14 Days
Check below for free stories on CNCE;EGRX;TLMR;IBP;HSNI;LINTA;DGX;LH;HAR;FLXN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 25, 2014
08:32 EDTDGXQuest Diagnostics price target raised to $74 from $68 at Maxim
Subscribe for More Information
July 24, 2014
07:05 EDTDGXQuest Diagnostics narrows 2014 adjusted EPS view to $4.00-$4.10 from $3.95-$4.15
Subscribe for More Information
07:02 EDTDGXQuest Diagnostics reports Q2 adjusted EPS $1.08, consensus $1.06
Subscribe for More Information
July 23, 2014
07:06 EDTEGRXEagle Pharmaceuticals says FDA approves Ryanodex for treatment of MH
Subscribe for More Information
July 22, 2014
07:08 EDTDGXLife Sciences highlights this week at Canaccord
Canaccord highlighted six diagnostic names that report this week and recommends buying Top Pick IDEXX (IDXX) into the print given strong recurring razor/razorblade sales and consistent organic growth. The analyst expects Hold rated Quest Diagnostics (DGX) to report upside to Street estimates of $1.06/$1.882B, Quidel (QDEL) to have an uneventful report, Exact Sciences (EXAS) to provide an update on numerous catalysts near-term and Abaxis (ABAX) to report earnings below consensus. Lastly, the firm is cautious on Meridian Bioscience (VIVO) following a competitor report last week.
July 21, 2014
08:09 EDTLHLabCorp price target raised to $130 from $120 at Maxim
Subscribe for More Information
July 18, 2014
12:04 EDTLHLabCorp pullback a buying opportunity, says Maxim
Subscribe for More Information
11:25 EDTLHPiper awaits notable volume recovery to get more positive on LabCorp
Piper Jaffray views LabCorp's in-line quarter as positive and said restored TRICARE coverage may provide added upside, but the firm would like to see notable lab volume recovery and a pullback in the shares before becoming more positive on the stock. Piper raised its price target on the stock to $99 from $98 and maintains its Neutral rating on LabCorp.
06:43 EDTLHLabCorp raises FY14 adjusted EPS to $6.50-$6.75 from $6.40-$6.70
Subscribe for More Information
06:43 EDTLHLabCorp: Q2 sales increase due to test volume
Total test volume increased 5.3%, while revenue per requisition decreased 2.0% due to test and payer mix. Reports Q2 operating income $246.7M, operating cash flow $207.4M, free cash flow $159M
06:41 EDTLHLabCorp reports Q2 adjusted EPS $1.84, consensus $1.77
Subscribe for More Information
July 17, 2014
09:34 EDTLHLabCorp upgraded to Outperform from Market Perform at William Blair
Subscribe for More Information
July 16, 2014
07:00 EDTCNCEConcert Pharmaceuticals says FDA lifts partial clinical hold for CTP-354
Concert Pharmaceuticals announced that the FDA has provided notification that the company has completed the necessary preclinical toxicology testing in order to administer repeated doses of CTP-354 in excess of 6 mg per day, lifting its partial clinical hold. As a result, the company intends to initiate dosing of 12 mg per day of CTP-354 in the third quarter of this year as part of its ongoing multiple ascending dose Phase 1 trial. Concert is initially developing CTP-354 for use in patients with spinal cord injury and in patients with multiple sclerosis to address significant unmet medical needs.
July 14, 2014
14:42 EDTHARHarman initiated with a Buy at Tigress Financial
Subscribe for More Information
08:59 EDTLHLabCorp management to meet with Maxim
Field trip to company lab to be held in New Jersey on July 15 hosted by Maxim.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use